Low-dose prophylaxis project begins in Pakistan

A project in Pakistan has begun, treating 25 children with a low-dose prophylaxis regimen. The objective is to demonstrate the benefits of this treatment regimen with regards to the improvement of the quality of life of children with hemophilia.

The project is being led by the Pakistan Hemophilia Patients Welfare Society (PHPWS) in Lahore, Pakistan, and was made possible thanks to the support of the World Federation of Hemophilia (WFH) Humanitarian Aid Program. The factor VIII concentrates used during this pilot project are from the donations from the WFH Humanitarian Aid Program Visionary Contributors. The goal of the pilot is to establish how low-dose prophylaxis could be rolled out to the greater Pakistani bleeding disorders community.

The parents of all participants were explained the process that their children would be following during the pilot, as well as the benefits of the program, during a seminar in Lahore, organized by the Pakistan Hemophilia Patients Welfare Society (PHPWS). The 25 children taking part in the pilot had never been part of a prophylaxis regimen, so the seminar featured several talks explaining how prophylaxis treatment helps to prevent musculoskeletal issues and life-threatening bleeds. Participants were also explained how starting prophylaxis at an early age prevents permanent joint damage. Another critical point that was explained was the importance of adhering to prescribed treatment schedules and going to a hemophilia treatment centre (HTC) for regular checkups.

It is hoped that this pilot program in Lahore is an important first step in the rolling out of low-dose prophylaxis regimens, in other HTCs in Pakistan. Studies from around the world have shown the strong potential benefits of this approach on the quality of life of people with hemophilia.


An increasing number of contributors within the global bleeding disorders community have accepted the challenge of providing a sustainable and predictable supply of donated products. The visionary contribution from Bioverativ and Sobi to the WFH Humanitarian Aid Program translates into 500 million IUs over five years (2015-2020). In addition, the eight-year commitment (2014-2021) from Grifols totaling 200 million IUs, along with a ten-year commitment (2009-2018) from CSL Behring for a total of 22 million IUs, and the three-year agreement (2017-2019) with Green Cross for 6 million IUs, there will now be a more predictable and sustainable flow of humanitarian aid donations to the global community. In addition, the initiatives of Project WISH and Project Recovery allow for the manufacturing of clotting factor concentrates from previously discarded cryopaste which provide treatment products to countries most in need.

Low dose pakistan7
Low dose pakistan6
Low dose pakistan5
Low dose pakistan4
Low dose pakistan3
Low dose pakistan2